AU2002335794A1 - Allylamides useful in the treatment of alzheimer's disease - Google Patents
Allylamides useful in the treatment of alzheimer's diseaseInfo
- Publication number
- AU2002335794A1 AU2002335794A1 AU2002335794A AU2002335794A AU2002335794A1 AU 2002335794 A1 AU2002335794 A1 AU 2002335794A1 AU 2002335794 A AU2002335794 A AU 2002335794A AU 2002335794 A AU2002335794 A AU 2002335794A AU 2002335794 A1 AU2002335794 A1 AU 2002335794A1
- Authority
- AU
- Australia
- Prior art keywords
- allylamides
- alzheimer
- disease
- useful
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32724301P | 2001-10-05 | 2001-10-05 | |
| US60/327,243 | 2001-10-05 | ||
| PCT/US2002/032010 WO2003030886A2 (en) | 2001-10-05 | 2002-10-04 | Allylamides useful in the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002335794A1 true AU2002335794A1 (en) | 2003-04-22 |
Family
ID=23275725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002335794A Abandoned AU2002335794A1 (en) | 2001-10-05 | 2002-10-04 | Allylamides useful in the treatment of alzheimer's disease |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050027007A1 (enExample) |
| EP (1) | EP1434580A2 (enExample) |
| JP (1) | JP2005508940A (enExample) |
| AU (1) | AU2002335794A1 (enExample) |
| BR (1) | BR0213138A (enExample) |
| CA (1) | CA2462875A1 (enExample) |
| MX (1) | MXPA04003244A (enExample) |
| WO (1) | WO2003030886A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| CN100475786C (zh) * | 2005-02-18 | 2009-04-08 | 中国科学院上海药物研究所 | 一类4-羟基戊酰胺类化合物及其制备方法和用途 |
| US7838676B2 (en) | 2005-11-21 | 2010-11-23 | Amgen Inc. | Beta-secretase modulators and methods of use |
| US7872009B2 (en) | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
| US7745484B2 (en) | 2005-11-21 | 2010-06-29 | Amgen Inc. | Beta-secretase modulators and methods of use |
| AU2006316620B2 (en) | 2005-11-21 | 2011-03-03 | Amgen Inc. | Beta-secretase modulators and methods of use |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| WO2008147544A1 (en) | 2007-05-25 | 2008-12-04 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| CL2008001500A1 (es) | 2007-05-25 | 2008-12-26 | Amgen Inc | Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros. |
| US7803809B2 (en) | 2008-11-12 | 2010-09-28 | Amgen Inc. | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use |
| WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
| WO2010030954A1 (en) | 2008-09-11 | 2010-03-18 | Amgen Inc. | Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use |
| US9296698B2 (en) | 2009-11-23 | 2016-03-29 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| US8822485B2 (en) | 2009-11-23 | 2014-09-02 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| US8735384B2 (en) | 2010-01-19 | 2014-05-27 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| ES2450568T3 (es) | 2010-03-15 | 2014-03-25 | Amgen Inc. | Compuestos espiero de amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso médico |
| CA2791281A1 (en) | 2010-03-15 | 2011-09-22 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta-secretase modulators |
| US9346827B2 (en) | 2011-02-07 | 2016-05-24 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use |
| WO2013044092A1 (en) | 2011-09-21 | 2013-03-28 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
| CN111087386B (zh) * | 2020-01-02 | 2020-12-18 | 牡丹江医学院 | 一种用于治疗阿尔茨海默病的化合物及其合成方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG52731A1 (en) * | 1991-11-08 | 1998-09-28 | Merck & Co Inc | Hiv protease inhibitors useful for the treatment of aids |
| NZ500868A (en) * | 1997-05-17 | 2001-08-31 | Glaxo Group Ltd | Antiviral combinations comprising 1592U89 and HIV protease inhibitors |
| US20020147197A1 (en) * | 1999-10-08 | 2002-10-10 | Newman Michael J. | Methods and compositions for enhancing pharmaceutical treatments |
| JP2003528071A (ja) * | 2000-03-23 | 2003-09-24 | エラン ファーマスーティカルズ インコーポレイテッド | アルツハイマー病治療用組成物および方法 |
| AU2001259817A1 (en) * | 2000-05-04 | 2001-11-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health | Methods of and compounds for inhibiting calpains |
-
2002
- 2002-10-04 MX MXPA04003244A patent/MXPA04003244A/es not_active Application Discontinuation
- 2002-10-04 US US10/491,841 patent/US20050027007A1/en not_active Abandoned
- 2002-10-04 WO PCT/US2002/032010 patent/WO2003030886A2/en not_active Ceased
- 2002-10-04 EP EP02770558A patent/EP1434580A2/en not_active Withdrawn
- 2002-10-04 BR BR0213138-2A patent/BR0213138A/pt not_active IP Right Cessation
- 2002-10-04 AU AU2002335794A patent/AU2002335794A1/en not_active Abandoned
- 2002-10-04 JP JP2003533918A patent/JP2005508940A/ja active Pending
- 2002-10-04 CA CA002462875A patent/CA2462875A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2462875A1 (en) | 2003-04-17 |
| US20050027007A1 (en) | 2005-02-03 |
| JP2005508940A (ja) | 2005-04-07 |
| BR0213138A (pt) | 2004-08-24 |
| WO2003030886A2 (en) | 2003-04-17 |
| WO2003030886A3 (en) | 2003-08-07 |
| MXPA04003244A (es) | 2004-07-08 |
| EP1434580A2 (en) | 2004-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1392287B8 (en) | Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease | |
| AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
| AU2001249835A1 (en) | Diagnosis and treatment of alzheimer's disease | |
| AU2001233299A1 (en) | Methods for treating alzheimer's disease | |
| AU2003206413A1 (en) | Substituted amino carboxamides for the treatment of alzheimer's disease | |
| AU2002306848A1 (en) | Methods of treating alzheimer's disease with piperidin derivates | |
| AU2002315131A1 (en) | Aminediols as agents for the treatment of alzheimer's disease | |
| AU2002319615A1 (en) | Methods for diagnosing and treating alzheimer's disease and parkinson's disease | |
| AU2002212471A1 (en) | Peptides for use in the treatment of alzheimer's disease | |
| AU2003209301A1 (en) | Treatments for neurotoxicity in alzheimer's disease | |
| AU2002222108A1 (en) | Diagnosis and treatment of alzheimer's disease | |
| AU2003303141A1 (en) | Hydroxypropyl amides for the treatment of alzheimer's disease | |
| IL160018A0 (en) | Isoxazolopyridinones and use thereof in the treatment of parkinson's disease | |
| AU2003238046A1 (en) | Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease | |
| AU2003273310A1 (en) | Substituted aminoethers for the treatment of alzheimer's disease | |
| AU2002312667A1 (en) | Individualization of therapy with alzheimer's disease agents | |
| AU2002357232A1 (en) | Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease | |
| AU2003299101A1 (en) | Compounds for the treatment of alzheimer's disease | |
| IL172213A0 (en) | Compounds useful in the therapy of alzheimer's disease and formulations containing them | |
| AU2003286530A1 (en) | Substituted peptides useful in the treatment of alzheimer's disease | |
| AU2003230848A1 (en) | Methods and compositions for treating alzheimer's disease | |
| AU2002348687A1 (en) | Macrocycles useful in the treatment of alzheimer's disease | |
| AU2002315098A1 (en) | Macrocycles useful in the treatment of alzheimer's disease | |
| AU2002346015A1 (en) | Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease | |
| AU2002364885A1 (en) | Alzheimer's disease model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |